Johnson & Johnson, the world's largest maker of medical devices, said second-quarter earnings dropped 27% on costs for acquisitions and a decline in revenue from its biggest drug, Procrit for anemia.
The company also said it was struggling to meet orders for the Cypher heart stent, a drug-coated mesh tube that keeps blood flowing through arteries.
